Beyond Obesity — Kisunla, Verzenio, and the Pipeline Most People Miss

Hiring managers at Lilly often complain that candidates only know the GLP-1 story and miss the much broader pipeline. Kisunla (donanemab) was Lilly's first-ever Alzheimer's medicine, approved in July 2024, and is reshaping early-disease neurology. Verzenio is delivering 7-year survival data in early breast cancer. Imlunestrant, olomorasib, and Jaypirca are deepening the oncology bench. This module gives you the non-GLP-1 portfolio fluency that signals to interviewers you actually understand the company.